Nav: Home

New flu drug drives drug resistance in influenza viruses

November 25, 2019

MADISON - On January 31, 2019, an 11-year old boy in Japan went to a medical clinic with a fever. The providers there diagnosed him with influenza, a strain called H3N2, and sent him home with a new medication called baloxavir.

For a few days, he felt better, but on February 5, despite taking the medication, his fever returned. Two days later, his 3-year-old sister also came down with a fever. She, too, was diagnosed with H3N2 influenza on February 8.

An analysis of flu samples collected from her and her brother show she was sickened by a strain of H3N2 harboring a new kind of mutation -- one that Yoshihiro Kawaoka, University of Wisconsin-Madison professor of pathobiological sciences, says is resistant to baloxavir, is just as capable of making people sick as the non-mutated version, and is capable of passing from person to person.

He and colleagues describe this in a study published today [Nov. 25, 2019] in Nature Microbiology that examined the effects of baloxavir treatment on influenza virus samples collected from patients before and after treatment.

"We sequenced the entire viral genome of the 11-year-old boy with drug sensitive influenza virus (before treatment) and the sample from the girl that is drug resistant," says Kawaoka. "Out of 13,133 nucleotides, there was only one nucleotide difference between the two."

In other words, what distinguished the virus collected from the brother before treatment and the virus collected from the sister later was a single mutation, a single change in just one letter among the more than 13,000 found in the genetic code of the virus.

"It tells you the virus acquired resistance during treatment and transmitted from brother to sister," Kawaoka explains.

Baloxavir is part of a new class of antiviral drugs that targets the machinery flu viruses use to copy their genetic material inside their human or animal hosts. It was first licensed in Japan, the United States, and in Hong Kong in 2018 and 2019. In fact, baloxavir represented 40 percent of the market share of influenza drugs in Japan during the 2018-2019 flu season. It will soon be licensed in 20 more countries, Kawaoka says.

However, as he and his co-authors note in the paper, clinical trial data on the drug revealed that some patients infected with either H3N2 or H1N1 influenza who took baloxavir developed a mutation at position 38 of the polymerase acidic protein, part of the virus's machinery that is targeted by the drug. A previous study by another group showed that the particular mutation had not been described among 17,000 H3N2 virus samples catalogued prior to December 2018.

"The new drug is safe, it went through phase three and was approved safety-wise, but even during clinical trials, the emergence of drug resistance was identified," Kawaoka explains.

In fact, a previous study in pediatric patients showed the mutation appeared in the samples collected from nearly 1 in 4 of the 77 children enrolled who were also treated with baloxavir.

"Baloxavir-resistant viruses emerge with a relatively high rate in kids" says Kawaoka, also a professor of virology at the University of Tokyo.

Given these findings, Kawaoka and his research team in Japan were interested in understanding the properties of H3N2 and H1N1 viruses -- commonly circulating strains that cause illness in people --before and after treatment with baloxavir.

During the 2018-2019 flu season, they set up a system to collect respiratory samples from patients before and after they received the new drug.

For H1N1 influenza, the researchers tested 74 samples from patients before treatment (10 adults and 64 children), and 22 samples from patients both before and after treatment (7 adults and 15 children). There were no instances of mutation in any of the samples before treatment, but there were mutations in one adult and four children after, or in about 23 percent of patients.

For H3N2, the team tested 141 patient samples before treatment (40 adults and 101 children), and two of those from children possessed the mutation. They also studied 16 patient samples before and after treatment (4 adults and 12 children), in which they found no mutations in adult samples but four of the child samples had the mutation.

Often, viruses that gain mutations such as drug resistance sacrifice their ability to survive and spread well among their hosts. To understand whether this was true of the baloxavir-driven mutation, the researchers grew the mutant viruses in cell culture and learned it grows just as well as the non-mutated form.

They then tested the mutant H1N1 and H3N2 viruses in hamsters and learned that once the virus mutates, that mutation continues to be copied as new virus grows.

The team also tested the mutated viruses in ferrets and found the mutated form was capable of transmitting from infected animals to healthy ones. The severity of their illness from flu was also similar to the non-mutated form.

While it's unlikely the mutation will lead to widespread resistance around the world, Kawaoka says it could become a problem among family members in close proximity, and in facilities like hospitals and nursing homes. And, while children seem particularly prone to viral mutation with baloxavir treatment, it appears to occur less frequently in adults. It also quickly reduces the amount of virus in the systems of treated patients. "It's a good drug for adults," Kawaoka says.

And, he explains, patients with H1N1 or H3N2 that do develop resistance to baloxavir with treatment still do respond to other virus-fighting drugs.

"The drug resistant virus does transmit but there are so many influenza viruses worldwide and only a small population will be treated with this drug," Kawaoka says. "The vast majority remain drug sensitive."
The study was funded by the Japan Agency for Medical Research and Development (JP18am001007, JP19fm0108006, JP19fk0108031, JP19fk0108056, JP19fk0108058 and JP19fk0108066); the Ministry of Education, Culture, Science, Sports and Technology of Japan (16H06429, 16K21723 and 16H06434); and the U.S. National Institute of Allergy and Infectious Diseases (HHSN27220140008C).

Author Makoto Yamashita has received a speaker's honoraria from Daiichi Sankyo Pharmaceutical. Yoshihiro Kawaoka has received a speaker's honoraria from Toyama Chemical and Astellas, and grant support from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Shionogi and Co., and Kyoritsu Seiyaku. Kawaoka is also founder of FluGen.

-- Kelly April Tyrrell,, 608-262-9772

University of Wisconsin-Madison

Related Influenza Articles:

Obesity promotes virulence of influenza
Obesity promotes the virulence of the influenza virus, according to a study conducted in mice published in mBio, an open-access journal of the American Society for Microbiology.
Influenza: combating bacterial superinfection with the help of the microbiota
Frenc researchers and from Brazilian (Belo Horizonte), Scottish (Glasgow) and Danish (Copenhagen) laboratories have shown for the first time in mice that perturbation of the gut microbiota caused by the influenza virus favours secondary bacterial superinfection.
Chemists unveil the structure of an influenza B protein
MIT chemists have discovered the structure of an influenza B protein called BM2, a finding that could help researchers design drugs that block the protein and help prevent the virus from spreading.
How proteins help influenza A bind and slice its way to cells
Researchers have provided new insight on how two proteins help influenza A virus particles fight their way to human cells.
Eating elderberries can help minimize influenza symptoms
Conducted by Professor Fariba Deghani, Dr. Golnoosh Torabian and Dr.
Mechanism to form influenza A virus discovered
A new study by Maria João Amorim's team, from the Gulbenkian Institute of Science, now reveals where the genomes of the influenza A virus are assembled inside infected cells.
Bat influenza viruses could infect humans
Bats don't only carry the deadly Ebola virus, but are also a reservoir for a new type of influenza virus.
New VaxArray publication on influenza neuraminidase quantification
InDevR Inc. announced publication of 'A Neuraminidase Potency Assay for Quantitative Assessment of Neuraminidase in Influenza Vaccines' in npj Vaccines.
Fighting mutant influenza
Another flu season is here, which means another chance for viruses to mutate.
Influenza vaccine delays are a problem for pediatricians
Uptake of influenza vaccine among children is low compared to other childhood vaccines, and missed opportunities for vaccination play an important role in this low uptake.
More Influenza News and Influenza Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at